Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -7.89% | -28.57% |
05-07 | Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-07 | Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024 |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.57% | 503M | - | ||
+17.96% | 44.96B | B- | ||
+1.17% | 42.65B | B | ||
+48.77% | 41.85B | A | ||
-4.27% | 29.04B | C | ||
+11.42% | 26.08B | B- | ||
-21.39% | 19.03B | B | ||
+4.86% | 12.75B | B+ | ||
+27.29% | 12.06B | C+ | ||
-3.50% | 11.75B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VLA Stock
- VLAP Stock
- Ratings Valneva SE Pref.